Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):41-46. doi: 10.1182/hematology.2019000012.

Emerging strategies in peripheral T-cell lymphoma.

Author information

1
Washington University in St. Louis, St. Louis, MO.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin lymphomas that are less chemosensitive than their B-cell counterparts. Until recently, standard therapy did not distinguish between subtypes, and deeper understanding of the biology of these diseases was lacking. The availability of targeted therapy and more sophisticated subtype classification has translated into the development of novel treatment options for these rare diseases. This includes the development of a brentuximab vedotin-based upfront chemotherapy regimen that confers an overall survival benefit for a subset of patients. Clinical trials of targeted agents, as well as development of better preclinical models of PTCL, are leading to therapeutic advances in the field, including the development of phosphoinositide-3-kinase inhibitors, histone deacetylase inhibitor-based strategies, CD30-directed strategies, Janus kinase inhibitors, and spleen-associated tyrosine kinase inhibitors. Better understanding of the biology of these diseases based on gene expression profiling, minimal residual disease evaluation, and modeling in patient-derived xenografts should help define mechanisms of response and resistance to therapy. Given the complex biology of these heterogeneous lymphomas, well-tolerated combination strategies targeted toward specific subtypes of PTCL can lead to advances in the field. Similar to the story of brentuximab vedotin, development of effective therapies in the salvage setting will likely lead to improved upfront strategies in PTCLs, and ultimately a more personalized approach.

PMID:
31808829
PMCID:
PMC6913433
[Available on 2020-12-06]
DOI:
10.1182/hematology.2019000012

Conflict of interest statement

Conflict-of-interest disclosure: N.M.-S. received research support from Bristol-Myers Squibb, Verastem Pharmaceuticals, Celgene, and Genentech/Roche; has served as a consultant for Kiowa Hakka Kirin; and receives support from the Lymphoma Research Foundation and the National Institutes of Health under Award K12CA167540.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center